Cytokeratin 6E inhibitors are a class of compounds designed to specifically target cytokeratin 6E, a member of the cytokeratin family of intermediate filament proteins. Cytokeratins are crucial for the structural integrity and mechanical resilience of epithelial cells, where they form networks of filaments that support the cellular architecture. Cytokeratin 6E, a type II keratin, is typically expressed in epithelial tissues, particularly those undergoing rapid turnover or subjected to stress, such as the epidermis and hair follicles. It works by pairing with type I keratins to form strong, flexible intermediate filaments that help cells withstand mechanical forces and maintain their structural integrity. Inhibitors of cytokeratin 6E interfere with these processes by blocking its normal filament-forming capabilities.
Cytokeratin 6E contains conserved alpha-helical domains, which enable it to assemble into coiled-coil dimers with other cytokeratins. These dimers further polymerize into filaments that are integral to the cytoskeleton. Inhibitors of cytokeratin 6E are thought to disrupt these structural elements, either by preventing the protein from dimerizing with its partners or by destabilizing the filament networks it forms. This inhibition leads to altered cytoskeletal organization within epithelial cells, potentially affecting their ability to respond to mechanical stress. By modulating the activity of cytokeratin 6E, these inhibitors serve as valuable tools for studying how intermediate filaments contribute to the overall structure, dynamics, and mechanical properties of epithelial tissues. Understanding the impact of these inhibitors on cytokeratin networks can provide insight into the fundamental processes of cellular structure and function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid, a histone deacetylase inhibitor, may downregulate CK6E expression through the alteration of chromatin compaction, allowing for the suppression of keratin-associated gene transcription. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
By inhibiting DNA methyltransferase, 5-Aza-2′-Deoxycytidine could lead to the demethylation of the CK6E gene promoter, resulting in the transcriptional silencing of this keratin gene. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram may decrease CK6E expression by hindering the NF-κB pathway, which is often involved in the transcriptional activation of various keratin genes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib might reduce CK6E levels by disrupting proteasomal degradation pathways, leading to an accumulation of proteins that repress transcription factors critical for CK6E gene expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, by inhibiting mTOR signaling, could lead to a decrease in the overall protein synthesis rates, including the synthesis of CK6E. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol, as a cyclin-dependent kinase inhibitor, may disrupt cell cycle progression and consequently downregulate CK6E gene transcription. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 could decrease CK6E expression by inhibiting the PI3K/AKT pathway, which is known to contribute to the transcriptional regulation of various keratins. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
As an MEK inhibitor, PD 98059 has the potential to inhibit the MAPK/ERK signaling pathway, which may lead to a decrease in transcription factors that drive CK6E expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, could decrease CK6E expression by preventing the activation of AP-1 transcription factors that are implicated in keratin gene expression. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib could inhibit CK6E expression by blocking EGFR signaling, which may be involved in keratin gene transcription regulation. | ||||||